Agenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average – Should You Sell?

Agenus Inc. (NASDAQ:AGEN)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.36 and traded as high as $8.00. Agenus shares last traded at $7.99, with a volume of 676,249 shares traded.

Analyst Ratings Changes

Several analysts have recently issued reports on AGEN shares. B. Riley Financial reiterated a “buy” rating and issued a $14.00 price objective (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Weiss Ratings cut Agenus from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, August 21st. HC Wainwright restated a “buy” rating and set a $25.00 price target (down from $30.00) on shares of Agenus in a report on Tuesday, August 11th. Wall Street Zen lowered Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. Finally, Zacks Research cut Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Agenus has an average rating of “Hold” and an average target price of $19.50.

Agenus Trading Up 1.9%

The company has a fifty day moving average price of $6.08 and a two-hundred day moving average price of $4.40. The firm has a market capitalization of $370.96 million, a PE ratio of 3.19 and a beta of 1.39.

Agenus (NASDAQ:AGEN) last announced its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The business had revenue of $34.52 million for the quarter, compared to analysts’ expectations of $34.00 million. Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. As a group, equities research analysts predict that Agenus Inc. will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

Several hedge funds have recently modified their holdings of the stock. EP Wealth Advisors LLC acquired a new stake in shares of Agenus in the 4th quarter worth $31,000. Jump Financial LLC purchased a new stake in Agenus during the second quarter worth $55,000. Squarepoint Ops LLC acquired a new stake in Agenus in the 3rd quarter valued at about $54,000. Redwood Family Wealth LLC acquired a new stake in shares of Agenus in the fourth quarter valued at approximately $44,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Agenus during the 3rd quarter valued at $64,000. 61.46% of the stock is owned by institutional investors and hedge funds.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.